Frazier-Backed Mavupharma Scores $20M to Fund STING Program Post author:Sam Post published:November 28, 2017 Post category:BioPharma The Series A funding will be used primarily to advance Mavu’s lead drug candidates into the clinic. Source: BioSpace You Might Also Like Dyadic Reports First Quarter 2017 Financial Results May 11, 2017 4 Biopharma Stocks a Billionaire Investor Just Bought February 16, 2017 Novartis Buys Rare Drug Voucher for $130M From Ultragenyx December 17, 2017